Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point ... Read ...

These include GlaxoSmithKline, though it is already looking to buy Novartis out of its joint venture in consumer health for around £8bn ($10.5bn). Others include Reckitt Benckiser, Procter ...

There were also strong gains for GSK's majority-owned HIV business ViiV Healthcare, up 19% to £1.5 billion, and anti-inflammatory medicines Nucala (mepolizumab) and Benlysta (belimumab).

News for GlaxoSmithKline Consumer Healthcare Ltd. Google.org Grants $1 Million to Karya for AI Upskilling in India Google.org awards USD 1 million to Karya, an Indian non-profit, to empower low-income ...

The modernization will enable the company to accommodate innovative technologies and expand its research capabilities. Governor Youngkin met with Haleon leadership in London in July 2024 to discuss ...

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...